Kiteskraft unveils their latest publication, The Power List to announce the mentors and change-makers that are shaping progress in India
CHANDIGARH, India, Feb. 12, 2026 /PRNewswire/ -- Kiteskraft Productions LLP proudly presents…
HarperCollins Publishers India Announces the Forthcoming Publication of Smarter Than the Storm, A New Book by Amitabh Kant and Siddharth Sinha
NEW DELHI, Feb. 6, 2026 /PRNewswire/ -- HarperCollins Publishers India is proud to…
HUTCHMED Highlights Publication of Phase III SACHI Results in The Lancet
— First randomized Phase III trial confirming the efficacy of MET inhibition…
Alchera X Advances Industry Leadership with Executive Feature in Leading Technology Publication during CES 2026 in Las Vegas
LOS ANGELES, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Alchera X (AX), a…
Oncotelic Therapeutics and Brush and Key Foundation Announce Publication in International Journal of Molecular Sciences Highlighting Context-Dependent Biomarkers in Liver and Pancreatic Cancer
AGOURA HILLS, Calif., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc.…
Ascentage Pharma Announces Publication of Olverembatinib Phase Ib Safety, Efficacy and Novel Mechanism Data in Gastrointestinal Stromal Tumors in Natures Signal Transduction and Targeted Therapy
Largest prospective clinical trial to-date in a rare subtype of GIST ROCKVILLE,…
Ajinomoto Bio-Pharma Services Wins “Best ADC Preclinical Publication 2024” Award for AJICAP Technology at 2025 World ADC Awards
Recognition underscores Ajinomoto Bio-Pharma Services' innovation and scientific excellence in advancing next-generation…
HarperCollins is proud to announce the publication of ‘The S.I.S. Story: How an accidental entrepreneur from Bihar created a global services conglomerate’ by Prince Mathews Thomas
Hardback | Non-Fiction/Memoir | 296 pp | INR 699 Available wherever books are sold |…
SpringWorks Therapeutics Announces Publication of Long-Term Efficacy and Safety Data from the Phase 3 DeFi Trial of OGSIVEO (nirogacestat) in Adults with Desmoid Tumors in the Journal of Clinical Oncology
Long-term continuous OGSIVEO treatment for up to 4 years was associated with…
Candel Therapeutics Announces Positive Interim Data After Repeated Administration of CAN-3110 in Recurrent Glioblastoma and Announces Publication in Science Translational Medicine
October 14, 2025 08:05 ET | Source: Candel Therapeutics NEEDHAM, Mass., Oct.…
